In laboratory settings, researchers utilize this compound in in-vitro and biochemical model systems to examine multi-receptor agonism, pathway cross-talk, and peptide-mediated regulatory mechanisms associated with metabolic signaling networks
Temperature proves critical
The second receptor is GIP, or glucose-dependent insulinotropic polypeptide
In the Phase 3 SURPASS-2 study, Mounjaro reduced A1C by 2% to 2.3% across its doses, compared to a 1.9% reduction for semaglutide at its 1 mg dose
Target levels of 30-50 ng/mL are appropriate for most patients, though specific populations may benefit from higher or lower targets based on their clinical circumstances
Incretin-Based Metabolic Therapies in Cardiovascular Medicine A Comprehensive Review of Clinical Outcomes, Pathophysiological Mechanisms, and Future Frontiers Index Terms atherosclerosis, cardiometabolic medicine, cardiorenal protection, cardiovascular outcomes trials, dipeptidyl peptidase-4 inhibitors, dual GIP/GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist, heart failure with preserved ejection fraction, plaque stabilization, semaglutide, tirzepatide, type 2 diabetes
